Dr Chari on Currently Available Bispecific Antibodies in Multiple Myeloma
Ajai Chari, MD, director, discusses the current landscape of bispecific antibodies in relapsed/refractory multiple myeloma.
Source: onclive.com
Page 3 - Myeloma Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Myeloma Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Myeloma Program Today - Breaking & Trending Today
Dr Chari on the Use of Ide-Cel and Cilta-Cel in Relapsed/Refractory Multiple Myeloma
Ajai Chari, MD, discusses the use of the CAR T-cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel in the treatment of patients with multiple myeloma.
Source: onclive.com
Dr Chari on the Selection of BCMA-Targeted Therapies Within Multiple Myeloma
Ajai Chari, MD, discusses important patient factors to consider when selecting between currently approved BCMA-targeted therapies for the treatment of patients with multiple myeloma.
Source: onclive.com
Chari Highlights Nuances of Choosing Between CAR T-cell Therapy and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
Without a plethora of randomized and historic data to compare treatments, selection and sequencing strategies for patients with relapsed/refractory multiple myeloma must balance a multitude of factors, including adverse effect profiles, disease resistance mechanisms, and more.
Source: onclive.com
Talquetamab Helps Usher in Era of Bispecific Antibodies in Relapsed/Refractory Myeloma
Ajai Chari, MD, discusses how the FDA approval of talquetamab addresses several unmet needs in relapsed/refractory multiple myeloma and expands on the agent’s efficacy data and safety profile observed in MonumenTAL-1.
Source: onclive.com